News – Page 891 – Endpoints News

FDA will convene adcomm for Bristol-Myers' Reblozyl in MDS; FDA grants 'orphan' tags to a trio of drugs

6 years ago

Merck in $1.3B showdown with insurers over 2017 ransomware attack — Bloomberg

6 years ago

Eager to tout pivotal win, Omeros however keeps key parameters shrouded

6 years ago

As it shops for new deals, Akcea hires former GSK exec as COO

6 years ago

In a win for industry, Trump administration issues scathing review of Pelosi drug pricing bill

6 years ago

An old, controversial Pfizer drug shows mid-stage efficacy against narcolepsy

6 years ago

Roche moves deeper into Merck territory with Tecentriq/chemo OK in frontline NSCLC

6 years ago

Antibody strategy to augment versatile immune cells sparks investment in French biotech

6 years ago

Biogen comes under renewed fire as a leading Alzheimer's expert raises serious questions about the aducanumab data

6 years ago

RAPT signs on with struggling Hanmi for Asian entrance of cancer therapy aimed at 'charged tumors'

6 years ago

Ardelyx reaches the 'capstone' in their third-straight positive PhIII – but many questions still linger

6 years ago

AbbVie picks first Alzheimer's, Parkinson's targets in Mission pact; Amarin files for Vascepa OK in Europe

6 years ago

Biogen boasts PhII win in lupus — will anyone turn their head from Alzheimer's to notice?

6 years ago

Struggling Adaptimmune gets a boost from the FDA as T cell cancer drug wins an inside track at the agency

6 years ago

Senate committee backs Stephen Hahn as the next FDA commissioner

6 years ago

On the heels of $225M royalty deal, Kodiak shoots for $250M raise to fund pivotal programs of its Eylea slayer

6 years ago

FDA ushers Merck's star cancer drug Keytruda toward another key checkpoint

6 years ago

Unlock the full Endpoints experience for your company — and support our mission of independent biopharma reporting

6 years ago

Publisher's note

FDA finalizes guidance on adaptive trial designs

6 years ago

Astellas snags a gene therapy upstart with $3B buyout bid — inspiring forecasts of more M&A ahead

6 years ago

FDA to Lexicon: Yeah, that's still gonna be a no from us

6 years ago

Incyte nabs priority review for bile duct cancer drug; Temasek shows interest in another Woodford darling — report

6 years ago

Pfizer's retired NASH drug shown to reduce liver fat, inspiring new faith in the DGAT2 pathway

6 years ago

Agios taps Bristol-Myers vet Bruce Car to replace retiring CSO

6 years ago

First page Previous page 888 889 890891892 893 894 Next page Last page